Sarah Boyce from Avidity Biosciences and Piratip Pratumsuwan from RTW Investments explore the strategic decisions and innovations that have driven Avidity's success. They cover her approach to overcoming the challenges of scaling a biotech company, the impact of Avidity’s groundbreaking work on treating rare genetic disorders, and Sarah’s vision for the future of RNA-based therapies.

PODCAST TEAM

Producer: Devon Leaver

Technical Director: Joseph Sebring

Editor: Dominique Guerra

Featuring: Sarah Boyce, President and CEO of Avidity Biosciences, and Piratip Pratumsuwan, Managing Director; Research Analyst at RTW Investments.

FOLLOW US

Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

CHAPTERS

00:00 - Introducing Sarah Boyce and Piratip Pratumsuwan

01:09 - Avidity Biosciences: Pioneering RNA therapeutics

02:20 - Joining Avidity: A bold decision

03:55 - Navigating challenges and embracing opportunities

12:00 - FSHD and Fortitude

18:21 - Looking Ahead: The future of RNA therapeutics

20:10 - Championing women in biotechnology

21:43 - Credits and disclaimer

DISCLAIMER

This interview and testimonial was given by Sarah Boyce, CEO of Avidity Biosciences, a company in which RTW has made an equity investment on behalf of its managed funds. No compensation was provided to Ms. Boyce.